Related Experiment Video

Updated: Jun 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity

S Corradini1, M Maksimos2, F Azab2

  • 1Research Centre for Health, School of Health and Life Sciences, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK.

Leukemia
|June 16, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Experiment Videos

Last Updated: Jun 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations.

Journal of medicinal chemistry·2026

A Direct-to-Biology Amine-Acid Amination for Rapid Phenotypic Profiling of Lysosomotropic Natural Products.

Journal of the American Chemical Society·2026

When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era.

Cancers·2026

Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

Journal of medicinal chemistry·2026

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.

Journal of medicinal chemistry·2026

Dental Educators' Perceptions of Factors Contributing to Their Well-being-A Qualitative Study.

European journal of dental education : official journal of the Association for Dental Education in Europe·2026

First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.

Leukemia·2026

Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.

Leukemia·2026

Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia.

Leukemia·2026

Exploiting an epigenetic resistance mechanism to PI3-kinase inhibition in leukemic stem cells.

Leukemia·2026

PIM1 in myeloproliferative neoplasms: potential pathogenic and therapeutic implications.

Leukemia·2026

Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s).

Leukemia·2026

Association of left atrioventricular coupling index with mortality in heart failure with preserved ejection fraction.

Acta cardiologica·2026

Multimodality Cardiovascular Imaging in the Evaluation of Cardiac Sarcoidosis.

JACC. Cardiovascular imaging·2026

Atrial Septal Defect Management Status and Long-Term Outcomes After Atrial Fibrillation Ablation: A Real-World Cohort Study.

Journal of cardiovascular electrophysiology·2026

Consensus-Recommended Follow-Up Mediates Cardiovascular Outcomes Disparities Between Implantable Cardioverter Defibrillator and Pacemaker Recipients.

Journal of cardiovascular electrophysiology·2026

Preparing HSCT and CAR‑T Therapy Programmes for JACIE Inspection: A Structured Methodological Approach to Implementing a Quality Management System.

International journal for quality in health care : journal of the International Society for Quality in Health Care·2026

Trends in Hyperkalemia-Related Sudden Cardiac Death Among Older Adults in the United States, 1999-2020.

Clinical cardiology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us